DaVita Inc. (NYSE:DVA) Position Boosted by Bank of Montreal Can

Bank of Montreal Can raised its holdings in DaVita Inc. (NYSE:DVA - Free Report) by 107.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 126,136 shares of the company's stock after purchasing an additional 65,207 shares during the quarter. Bank of Montreal Can owned 0.15% of DaVita worth $18,864,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently modified their holdings of the company. Amundi boosted its holdings in DaVita by 116.4% during the fourth quarter. Amundi now owns 446,386 shares of the company's stock worth $68,726,000 after buying an additional 240,126 shares in the last quarter. Skandinaviska Enskilda Banken AB publ grew its holdings in shares of DaVita by 256.8% in the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 162,233 shares of the company's stock worth $24,301,000 after acquiring an additional 116,758 shares during the period. JPMorgan Chase & Co. raised its holdings in DaVita by 17.8% during the third quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company's stock worth $99,846,000 after purchasing an additional 92,014 shares during the last quarter. California Public Employees Retirement System grew its holdings in DaVita by 75.1% in the fourth quarter. California Public Employees Retirement System now owns 196,788 shares of the company's stock valued at $29,430,000 after purchasing an additional 84,375 shares during the last quarter. Finally, Strategic Financial Concepts LLC acquired a new position in shares of DaVita during the 4th quarter worth $9,371,000. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

DaVita Stock Down 0.4 %

Shares of DaVita stock traded down $0.55 during trading hours on Thursday, hitting $140.96. 352,642 shares of the company's stock traded hands, compared to its average volume of 829,428. DaVita Inc. has a twelve month low of $125.64 and a twelve month high of $179.60. The company has a market cap of $11.28 billion, a PE ratio of 13.10, a PEG ratio of 1.07 and a beta of 1.04. The company has a quick ratio of 1.21, a current ratio of 1.26 and a debt-to-equity ratio of 23.18. The stock has a 50 day simple moving average of $150.47 and a 200-day simple moving average of $156.34.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings results on Thursday, February 13th. The company reported $2.24 EPS for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. Equities research analysts anticipate that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on DVA. Sanford C. Bernstein set a $184.00 price target on shares of DaVita in a report on Friday, February 21st. Barclays upped their price objective on DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Tuesday, February 18th. Cowen restated a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. Finally, StockNews.com raised shares of DaVita from a "hold" rating to a "buy" rating in a research report on Thursday, April 10th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $166.33.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.